论文部分内容阅读
目的探讨雷公藤多甙及米非司酮用于重度盆腔子宫内膜异位症(内异症)腹腔镜术后辅助药物治疗的疗效及副反应。方法对广东省妇幼保健院1998年1月至2003年1月240例重度盆腔子宫内异症患者腹腔镜术后随访资料进行回顾性分析,比较术后应用雷公藤多甙及米非司酮与单一应用米非司酮、雷公藤多甙治疗后的复发率和副反应发生率。结果雷公藤多甙及米非司酮(雷+米)组的复发率为8.7%,显著低于米非司酮组的13.7%(P<0.05),亦显著低于雷公藤多甙组的17.5%(P<0.05)。雷公藤多甙及米非司酮组肝功能损害发生率为6.3%,显著低于米非司酮组的13.8%(P<0.05),其白细胞减少发生率为5.0%,显著低于雷公藤多甙组的8.8%(P<0.05)。结论雷公藤多甙及米非司酮用于重度盆腔子宫内膜异症腹腔镜术后的治疗较单一米非司酮或雷公藤多甙治疗,能显著降低内异症的复发率,并能显著降低药物副反应率。
Objective To investigate the efficacy and side effects of tripterygium glycosides and mifepristone for adjuvant drug therapy after severe laparoscopic surgery for pelvic endometriosis (endometriosis). Methods The follow-up data of 240 patients with severe pelvic endometriosis from January 1998 to January 2003 in Guangdong Maternal and Child Health Hospital were retrospectively analyzed. The data of postoperative application of tripterygium glycosides and mifepristone Single application of mifepristone, tripterygium glycosides after treatment of the recurrence rate and incidence of side effects. Results The relapse rate of tripterygium glycosides and mifepristone (Ray + m) group was 8.7%, significantly lower than 13.7% (P <0.05) in the mifepristone group and significantly lower than that in the tripterygium glycosides group 17.5% (P <0.05). The incidence of hepatic dysfunction in tripterygium glycosides and mifepristone group was 6.3%, significantly lower than that in the mifepristone group (13.8%, P <0.05). The incidence of leukopenia was 5.0%, which was significantly lower than that in the tripterygium wilfordii Polyglucoside group 8.8% (P <0.05). Conclusion Tripterygium glycosides and mifepristone for the treatment of severe pelvic endometriosis after laparoscopic single mifepristone or tripterygium glycosides treatment can significantly reduce the recurrence rate of endometriosis and can Significantly reduce the rate of adverse drug reactions.